Moleculin Biotech Presents Data On Annamycin At IASLC 2024, Showing Significant Tumor Growth Inhibition And Extended Survival In Lung Cancer Models With 100% Non-Cardiotoxicity
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech presented data at IASLC 2024 on Annamycin, demonstrating significant tumor growth inhibition and extended survival in lung cancer models, with 100% non-cardiotoxicity.

September 23, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moleculin Biotech's Annamycin data presented at IASLC 2024 shows significant tumor growth inhibition and extended survival in lung cancer models, with 100% non-cardiotoxicity, potentially boosting investor confidence.
The presentation of Annamycin's data at a major conference like IASLC 2024, showing significant tumor growth inhibition and non-cardiotoxicity, is likely to boost investor confidence in Moleculin Biotech. This could lead to a positive short-term impact on MBRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100